Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.50
OTCPK:IDRSF's Cash-to-Debt is ranked lower than
70% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. OTCPK:IDRSF: 1.50 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:IDRSF' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.5  Med: 1.69 Max: 2.48
Current: 1.5
1.5
2.48
Equity-to-Asset 0.56
OTCPK:IDRSF's Equity-to-Asset is ranked lower than
63% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OTCPK:IDRSF: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:IDRSF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.56  Med: 0.57 Max: 0.58
Current: 0.56
0.56
0.58
Debt-to-Equity 0.55
OTCPK:IDRSF's Debt-to-Equity is ranked lower than
67% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. OTCPK:IDRSF: 0.55 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:IDRSF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.48  Med: 0.54 Max: 0.73
Current: 0.55
0.48
0.73
Debt-to-EBITDA 9.29
OTCPK:IDRSF's Debt-to-EBITDA is ranked lower than
100% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. OTCPK:IDRSF: 9.29 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OTCPK:IDRSF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.96  Med: 83.59 Max: 168.13
Current: 9.29
-0.96
168.13
Interest Coverage 3.36
OTCPK:IDRSF's Interest Coverage is ranked lower than
99.99% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCPK:IDRSF: 3.36 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:IDRSF' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.71
Current: 3.36
0
3.71
Altman Z-Score: 3.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % 17.74
OTCPK:IDRSF's Operating Margin % is ranked higher than
68% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. OTCPK:IDRSF: 17.74 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:IDRSF' s Operating Margin % Range Over the Past 10 Years
Min: -4.99  Med: -4.99 Max: 17.74
Current: 17.74
-4.99
17.74
Net Margin % 13.24
OTCPK:IDRSF's Net Margin % is ranked higher than
67% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. OTCPK:IDRSF: 13.24 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:IDRSF' s Net Margin % Range Over the Past 10 Years
Min: -9.03  Med: -9.03 Max: 13.24
Current: 13.24
-9.03
13.24
ROE % 3.35
OTCPK:IDRSF's ROE % is ranked higher than
74% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. OTCPK:IDRSF: 3.35 )
Ranked among companies with meaningful ROE % only.
OTCPK:IDRSF' s ROE % Range Over the Past 10 Years
Min: -65.42  Med: -33.85 Max: 3.35
Current: 3.35
-65.42
3.35
ROA % 1.94
OTCPK:IDRSF's ROA % is ranked higher than
76% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. OTCPK:IDRSF: 1.94 )
Ranked among companies with meaningful ROA % only.
OTCPK:IDRSF' s ROA % Range Over the Past 10 Years
Min: -36.62  Med: -18.96 Max: 1.94
Current: 1.94
-36.62
1.94
ROC (Joel Greenblatt) % 10.60
OTCPK:IDRSF's ROC (Joel Greenblatt) % is ranked higher than
75% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. OTCPK:IDRSF: 10.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:IDRSF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -204.17  Med: -103.73 Max: 10.6
Current: 10.6
-204.17
10.6
GuruFocus has detected 3 Warning Signs with Idorsia Ltd OTCPK:IDRSF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:IDRSF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:IDRSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:ACAD, SZSE:002603, NAS:CLVS, SZSE:000990, SHSE:600161, HKSE:00570, SZSE:300009, XTER:MOR, NAS:CBPO, XKRX:084990, NAS:HALO, NAS:ASND, NAS:PBYI, NAS:ANAB, NAS:FOLD, NYSE:EBS, XBRU:ARGX, SZSE:002821, XSWX:GALE, NAS:CRSP » details
Traded in other countries:19T.Germany, IDIA.Switzerland, 0RQE.UK,
Headquarter Location:Switzerland
Idorsia Ltd is a biopharmaceutical company specialized in the discovery, development and commercialization of molecule therapeutics to treat central nervous system, cardiovascular disorders, immunological disorders and orphan diseases.

Idorsia Ltd is an independent biopharmaceutical company specialized in the discovery, development and commercialization of small molecule therapeutics to treat central nervous system, cardiovascular disorders, immunological disorders and orphan diseases.

Top Ranked Articles about Idorsia Ltd

Vanguard Health Care Fund Gains 4 International Stocks in 2nd Quarter 2 positions are in newly public companies
Vanguard Health Care Fund (Trades, Portfolio) portfolio manager Jean Hynes invested in four international health care companies during the second quarter. Her new holdings are in Sysmex Corp. (TSE:6869), Terumo Corp. (TSE:4543), WuXi Biologics (Cayman) Inc. (HKSE:02269) and Idorsia Ltd. (XSWX:IDIA). Read more...

Ratios

vs
industry
vs
history
PE Ratio 119.10
IDRSF's PE Ratio is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. IDRSF: 119.10 )
Ranked among companies with meaningful PE Ratio only.
IDRSF' s PE Ratio Range Over the Past 10 Years
Min: 115.72  Med: 127.21 Max: 133.99
Current: 119.1
115.72
133.99
PE Ratio without NRI 119.10
IDRSF's PE Ratio without NRI is ranked lower than
99.99% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. IDRSF: 119.10 )
Ranked among companies with meaningful PE Ratio without NRI only.
IDRSF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 115.72  Med: 127.21 Max: 133.99
Current: 119.1
115.72
133.99
PB Ratio 3.82
IDRSF's PB Ratio is ranked higher than
56% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. IDRSF: 3.82 )
Ranked among companies with meaningful PB Ratio only.
IDRSF' s PB Ratio Range Over the Past 10 Years
Min: 3.37  Med: 4.13 Max: 4.76
Current: 3.82
3.37
4.76
PS Ratio 15.51
IDRSF's PS Ratio is ranked lower than
99.99% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IDRSF: 15.51 )
Ranked among companies with meaningful PS Ratio only.
IDRSF' s PS Ratio Range Over the Past 10 Years
Min: 15.07  Med: 17.42 Max: 22.44
Current: 15.51
15.07
22.44
Price-to-Free-Cash-Flow 22.22
IDRSF's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. IDRSF: 22.22 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IDRSF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 21.58  Med: 28.94 Max: 40.41
Current: 22.22
21.58
40.41
Price-to-Operating-Cash-Flow 21.04
IDRSF's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. IDRSF: 21.04 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IDRSF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 20.44  Med: 26.62 Max: 37.18
Current: 21.04
20.44
37.18
EV-to-EBIT 80.93
IDRSF's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. IDRSF: 80.93 )
Ranked among companies with meaningful EV-to-EBIT only.
IDRSF' s EV-to-EBIT Range Over the Past 10 Years
Min: -416.5  Med: -288.8 Max: 93.5
Current: 80.93
-416.5
93.5
EV-to-EBITDA 59.96
IDRSF's EV-to-EBITDA is ranked lower than
99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. IDRSF: 59.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
IDRSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 58.1  Med: 957.75 Max: 1381.5
Current: 59.96
58.1
1381.5
EV-to-Revenue 14.37
IDRSF's EV-to-Revenue is ranked lower than
52% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. IDRSF: 14.37 )
Ranked among companies with meaningful EV-to-Revenue only.
IDRSF' s EV-to-Revenue Range Over the Past 10 Years
Min: 14.2  Med: 16.1 Max: 20.8
Current: 14.37
14.2
20.8
Current Ratio 11.38
IDRSF's Current Ratio is ranked higher than
78% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. IDRSF: 11.38 )
Ranked among companies with meaningful Current Ratio only.
IDRSF' s Current Ratio Range Over the Past 10 Years
Min: 9.07  Med: 11.41 Max: 18.99
Current: 11.38
9.07
18.99
Quick Ratio 11.38
IDRSF's Quick Ratio is ranked higher than
79% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. IDRSF: 11.38 )
Ranked among companies with meaningful Quick Ratio only.
IDRSF' s Quick Ratio Range Over the Past 10 Years
Min: 9.07  Med: 11.41 Max: 18.99
Current: 11.38
9.07
18.99

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 131.88
IDRSF's Price-to-Net-Cash is ranked lower than
99.99% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. IDRSF: 131.88 )
Ranked among companies with meaningful Price-to-Net-Cash only.
IDRSF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 13.21  Med: 30.57 Max: 146.13
Current: 131.88
13.21
146.13
Price-to-Net-Current-Asset-Value 9.81
IDRSF's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. IDRSF: 9.81 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
IDRSF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.4  Med: 8.31 Max: 10.72
Current: 9.81
6.4
10.72
Price-to-Tangible-Book 3.83
IDRSF's Price-to-Tangible-Book is ranked higher than
63% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. IDRSF: 3.83 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IDRSF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.88  Med: 3.56 Max: 4.18
Current: 3.83
2.88
4.18
Price-to-Median-PS-Value 0.89
IDRSF's Price-to-Median-PS-Value is ranked lower than
99.99% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. IDRSF: 0.89 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IDRSF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.87  Med: 1.02 Max: 1.09
Current: 0.89
0.87
1.09
Price-to-Graham-Number 4.47
IDRSF's Price-to-Graham-Number is ranked lower than
99.99% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. IDRSF: 4.47 )
Ranked among companies with meaningful Price-to-Graham-Number only.
IDRSF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 4.34  Med: 4.78 Max: 4.88
Current: 4.47
4.34
4.88
Earnings Yield (Greenblatt) % 1.24
IDRSF's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. IDRSF: 1.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IDRSF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.4  Med: -0.2 Max: 1.28
Current: 1.24
-0.4
1.28

More Statistics

Revenue (TTM) (Mil) $167.09
EPS (TTM) $ 0.16
52-Week Range $16.98 - 33.02
Shares Outstanding (Mil)119.12

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}